Company intelligence / Profile preview

Eternal

Buenos Aires, Argentinaeternal.co ↗

Ownership: Private
Development stage: Other

Overview

Eternal has developed an advanced precision fermentation system to create high-quality, animal-free mycoprotein ingredients. Their flagship product "Mycofood" is used as the basis for meat analogues such as chicken breast alternatives. The company is recognized for its innovation in sustainable protein production and was a finalist in both the NASA Deep Space Food Challenge and XPRIZE Feed the Next Billion competitions. Their technology leverages AI-driven optimization of fungal fermentation processes to maximize nutritional value while minimizing environmental impact.

Industry: Non-Drug Biotech

Partnerships

Finalist partnerships with NASA/XPRIZE; no major pharma or biotech partners disclosed

Beyond the preview

Go deeper on Eternal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eternal.

Explore the full profile